Overview of Advances in Imaging in Prostate Cancer

A panel of experts on prostate cancer provide an overview of conventional imaging modalities that have been used in the initial staging and management of prostate cancer and discuss the role of PSMA-PET imaging.

Now Viewing

EP: 1.Overview of Advances in Imaging in Prostate Cancer

EP: 2.The Impact of PSMA-PET Imaging in Prostate Cancer

EP: 3.Identifying the Right Patient Population for PSMA-PET Imaging

EP: 4.PSMA-PET Imaging in the Biochemical Recurrence Setting

EP: 5.The Impact of PSMA-PET Imaging on Treatment Decisions

EP: 6.The Role for PSMA-PET Imaging in Active Surveillance

EP: 7.When and How Often PSMA-PET Imaging Should be Used

EP: 8.Monitoring Treatment Response

EP: 9.Unmet Needs and Challenges in Imaging of Prostate Cancer

EP: 10.The Value of Multidisciplinary Care in PSMA-PET Imaging

EP: 11.Future Directions in PSMA-PET Imaging

EP: 12.PSMA-PET Imaging for Prostate Cancer: Perspectives From a Nuclear Radiologist

EP: 13.Similarities and Differences Among PSMA-PET Tracers

EP: 14.Tips for Improving the Interpretation and Reporting of PSMA-PET Imaging Results

Related Videos

Related Content

Advertisement

March 11th 2025

Phase 3 trial launches of ArteraAI Prostate test for treatment selection

Hannah Clarke

The goal of the trial is to improve quality of life by identifying patients who can safely reduce or avoid treatment with hormone therapy.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

March 5th 2025

Trial of 64Cu/67Cu-SAR-bisPSMA in mCRPC progresses to dose expansion phase

Hannah Clarke

The safety review committee recommended that the phase 2 portion proceed with the 8 GBq dose.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

March 3rd 2025

FDA updates in urology: February 2025

Hannah Clarke

A recap of the FDA submissions and regulatory decisions in urology from February 2025.

February 27th 2025

Enrollment goal met in trial of Vanquish device for localized prostate cancer

Hannah Clarke

Data from the VAPOR 2 trial are intended to support a submission to the FDA for 510(k) clearance of the device.

Related Content

Advertisement

March 11th 2025

Phase 3 trial launches of ArteraAI Prostate test for treatment selection

Hannah Clarke

The goal of the trial is to improve quality of life by identifying patients who can safely reduce or avoid treatment with hormone therapy.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

March 5th 2025

Trial of 64Cu/67Cu-SAR-bisPSMA in mCRPC progresses to dose expansion phase

Hannah Clarke

The safety review committee recommended that the phase 2 portion proceed with the 8 GBq dose.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

March 3rd 2025

FDA updates in urology: February 2025

Hannah Clarke

A recap of the FDA submissions and regulatory decisions in urology from February 2025.

February 27th 2025

Enrollment goal met in trial of Vanquish device for localized prostate cancer

Hannah Clarke

Data from the VAPOR 2 trial are intended to support a submission to the FDA for 510(k) clearance of the device.